A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases

This is a single-arm, multicenter, phase II clinical trial evaluating the safety and efficacy of neoadjuvant encorafenib plus cetuximab N01 and mFOLFOX6 in patients with locally advanced BRAF V600E-mutated colorectal cancer, with or without resectable metastases. Eligible patients will receive 8 weeks of neoadjuvant treatment with encorafenib, cetuximab N01, and mFOLFOX6, followed by tumor response assessment and radical surgery when appropriate. The primary endpoint is 18-month disease-free survival (DFS). Secondary endpoints include perioperative safety, objective response rate, pathological

Trial Details

NCT ID
NCT07789210
Phase
PHASE2
Sponsor
Zhejiang University
Status
RECRUITING
Cancer Type
Rectal Cancer Colorectal Cancer
Interventions
  • Neoadjuvant therapy of encorafenib plus cetuximab N01 and mFOLFOX6
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;
  • Age: 18-75 years old, PS score 0-1;
  • Colorectal adenocarcinoma diagnosed by histopathology, preoperative staging: T4N0-2M0, T3N2M0, T0-4N0-2M1a (with metastatic lesions present, requir…
  • Locally advanced colorectal cancer requires initial diagnosis of patients who have not received systematic treatment in the past. Patients with res…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Rectal Cancer Colorectal Cancer Trials on Trialify →